Overview
Mermaid diagram (expand to render)
Blackrock Neurotech is a pioneer in brain-computer interface (BCI) technology, headquartered in Salt Lake City, Utah["@blackrock2024"]. Founded in 2008 as a spinout from the University of Utah, Blackrock is widely recognized as the leading provider of implantable neural recording technology, with their Utah Array becoming the gold standard for chronic neural interfaces in research and clinical applications.
Blackrock's Utah Array has been implanted in more patients than any other invasive BCI system, making it the most clinically validated invasive BCI technology available today["@hochberg2006"]. The company has a long-standing track record of enabling breakthrough neuroscience research and recently received FDA approval for their first commercial neural interface system.
Technology
The Utah Array represents the culmination of decades of neural interface development, combining sophisticated engineering with extensive clinical validation to become the most widely used implantable BCI technology globally[@lakatos2014].
Utah Array
The Utah Array is Blackrock's flagship product — a microelectrode array designed for chronic implantation in the brain[@blackrock2024]:
Specifications:
- Electrode count: 100-128 electrodes per array
- Electrode spacing: 400 microns
- Shank length: 1-1.5 mm (varies by application)
- Material: Silicon substrate with platinum/iridium tips
- Recording sites: Individual electrodes can record single-unit activity
- Bandwidth: High-fidelity single-unit and local field potential recording
Design Principles:
- Proven long-term stability (years of recording)
- FDA-approved for clinical use
- Modular configuration (multiple arrays can be implanted)
- Compatible with standard neural recording systems
Design and Manufacturing
The Utah Array employs precise microfabrication techniques developed at the University of Utah:
Silicon Processing
- Photolithographic patterning creates individual electrode shanks
- Reactive ion etching defines shank geometry
- Platinum deposition creates conductive recording sites
- Insulating parylene-C coating protects interconnects
Clinical Design Considerations
- Minimally invasive implantation through small burr holes
- Modular arrays enabling coverage of multiple brain regions
- Percutaneous connectors for reliable signal transmission
- Scalable design supporting incremental channel expansion
Signal Quality and Capabilities
The Utah Array provides exceptional neural recording capabilities:
Single-Unit Recording
- Isolation of individual neuron action potentials
- Spike sorting for multi-unit discrimination
- Stable unit identification over months of recording
- High signal-to-noise ratio (typically >5:1)
Local Field Potentials
- Recording of slower network dynamics
- Frequency-specific analysis (gamma, beta, alpha bands)
- Correlation with movement parameters
- Integration with spike-based decoding
Product Portfolio
| Product | Application | Status |
|---------|-------------|--------|
| Utah Array | Research/Clinical | FDA Approved |
| MoveAgain BCI | Motor restoration | FDA Approved |
| Neuralace | High-density (10,000+ electrodes) | Development |
| Cereplex System | Wireless recording | Research |
Future Technologies
Neuralace
The Neuralace represents Blackrock's next-generation approach:
- Ultra-high-density array with 10,000+ electrodes
- Flexible substrate conforming to brain curvature
- Wireless data transmission eliminating percutaneous connections
- Integrated processing for on-device decoding
Wireless SystemsFuture developments include fully implantable systems:
- No external connections reducing infection risk
- Rechargeable or energy-harvesting power systems
- Integrated signal processing
- Seamless user experience
Clinical Applications
Blackrock Neurotech's technology has been central to groundbreaking clinical demonstrations of BCI capability, establishing benchmarks for what is possible with invasive neural interfaces[@colline2012]. These applications span [neurodegenerative diseases](/diseases/neurodegeneration), [motor disorders](/diseases/movement-disorders), and [neurological injuries](/diseases/neurological-injury).
Current Indications
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis): Communication devices for patients with locked-in syndrome
[Spinal Cord Injury](/diseases/spinal-cord-injury): Motor restoration for quadriplegia
[Stroke](/diseases/stroke): Rehabilitation and motor function recovery
[Parkinson's Disease](/diseases/parkinsons-disease): Neural monitoring for [DBS optimization](/treatments/deep-brain-stimulation)
[Multiple Sclerosis](/diseases/multiple-sclerosis): Upper extremity function preservation
[Alzheimer's Disease](/diseases/alzheimers-disease): Neural recording for cognitive decline researchMoveAgain BCI System
Blackrock's MoveAgain BCI received FDA breakthrough device designation and represents the company's first commercial product for patients with paralysis[@blackrock2024a]:
- Enables wireless control of computers and devices
- Clinically validated in multiple patients
- FDA approved for clinical use
- Supports cursor control, text entry, and device switching
- Intended for individuals with upper limb paralysis
Historical Clinical Milestones
First Demonstration (2006)
The seminal study by Hochberg et al. demonstrated that neural signals could control external devices:
- A patient with tetraplegia controlled a computer cursor
- Point-and-click accuracy achieved through motor cortex signals
- Demonstrated feasibility of neural prosthetic control[@hochberg2006]
High-Performance Control (2013)Collinger et al. achieved unprecedented control quality:
- 7 degrees of freedom control of a robotic arm
- Near-natural movement trajectories
- Successful feeding and drinking tasks[@colline2012]
Communication Applications (2015)Gilja et al. demonstrated high-performance communication:
- Text entry rates of 8-10 words per minute
- Accuracy exceeding 90% with error correction
- Real-world utility for daily communication[@gilja2015]
Recent Advances (2019-2023)Willett et al. demonstrated rapid, accurate typing:
- 62 characters per minute with a neural interface
- Personalized language models improved accuracy
- Closed-loop feedback enhanced control[@willett2019]
Research Applications
- [Alzheimer's disease](/diseases/alzheimers-disease) research (neural recording)
- [Epilepsy](/diseases/epilepsy) monitoring and [seizure prediction](/biomarkers/seizure-biomarkers)
- [Brain-machine interface](/technologies/brain-computer-interfaces) research
- [Neuroscience](/mechanisms/neuroscience) studies of [motor cortex](/brain-regions/motor-cortex) function
- [Cognitive neuroscience](/mechanisms/cognitive-neuroscience) and [memory](/mechanisms/memory-consolidation) research
- [Neuroprosthetic](/technologies/neuroprosthetics) development
Competitive Advantages
Blackrock Neurotech maintains a leading position in the invasive BCI market through several key differentiators:
Advantages
Longest Clinical Track Record: Most widely used invasive BCI with data spanning over 15 years of clinical use
FDA Approved: Only FDA-approved implantable neural array for clinical use in the United States
Proven Durability: Documented stable recording for 5+ years in some patients
Research Infrastructure: Established ecosystem of tools, software, and support services
Clinical Validation: Extensive human trial data with peer-reviewed publications
Established Manufacturing: Scalable production capabilities with consistent quality
Clinical Network: Relationships with leading research hospitals and cliniciansChallenges
Invasive: Requires surgical implantation with associated risks
Limited Channel Count: 100-128 channels compared to newer technologies offering 1,000+
Wired Connection: Traditional systems require percutaneous connection
Foreign Body Response: Glial scarring affects signal quality over time
Cost: High initial investment for implantation and maintenanceComparison with Competing Technologies
| Feature | Blackrock Utah Array | Neuralink | Synchron |
|---------|---------------------|-----------|----------|
| Electrodes | 100-128 | 1,024 | 16 |
| Invasive | Yes (intracortical) | Yes (intracortical) | Yes (endovascular) |
| Wireless | Optional | Yes | Yes |
| FDA Status | Approved | Trial | Trial |
| Clinical Years | 15+ | 1 | 2 |
Safety and Regulatory
Safety Profile
Clinical data from the BrainGate consortium and other studies demonstrate the safety of Utah Array implantation[@rubin2023]:
Surgical Risks
- Low rate of serious adverse events
- No cases of infection requiring device removal in recent trials
- Transient discomfort at implant site most common complaint
Long-Term Safety
- Stable recording quality maintained over years
- No significant deterioration in most patients
- Device replacement rarely required
Regulatory Milestones
- FDA Approval: Utah Array approved for clinical neural recording
- FDA Breakthrough Device: MoveAgain BCI received breakthrough designation
- Clinical Trials: Multiple ongoing studies expanding indications
Research Publications
Key Publications
Hochberg LR, et al. Neuronal ensemble control of prosthetic devices by a human with tetraplegia. Nature. 2006[@hochberg2006].
Gilja V, et al. Clinical translation of a high-performance neural prosthesis. Nature Medicine. 2015[@gilja2015].
Collinger JL, et al. High-performance neuroprosthetic control by an individual with tetraplegia. Lancet. 2013[@colline2012].
Willett FR, et al. Neural control of computer cursor with rapid, accurate typing. eLife. 2019[@willett2019].
Rubin DB, et al. Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System. Neurology. 2023[@rubin2023].
Simeral JD, et al. Neural control of cursor trajectory by human motor cortex. Neural Networks. 2011[@simeral2014].
Jarosiewicz B, et al. Performance of a neural interface device in people with tetraplegia. Journal of Neural Engineering. 2015[@jarosiewicz2015].Technical Specifications
Array Configuration
| Parameter | Specification |
|-----------|---------------|
| Electrodes per Array | 100-128 |
| Shank Length | 1.0-1.5 mm |
| Shank Width | 50-80 μm |
| Electrode Spacing | 400 μm |
| Recording Sites | 1-2 per shank tip |
| Substrate | Silicon |
| Conductor | Platinum/iridium |
Recording Characteristics
| Parameter | Value |
|-----------|-------|
| Signal Bandwidth | 0.3 Hz - 7.5 kHz |
| Sampling Rate | 30 kHz |
| Input Impedance | >1 GΩ |
| Noise Level | <5 μV RMS |
| Common Mode Rejection | >80 dB |
Future Directions
Blackrock Neurotech is pursuing several development paths to enhance BCI capabilities:
Near-Term Developments
Wireless Systems
- Eliminating percutaneous connections
- Reducing infection risk
- Improving user experience
- Enabling continuous monitoring
Increased Channel Count
- Multi-array implantation
- Higher density arrays
- Broader brain coverage
Long-Term Vision
Neuralace Platform
- Ultra-high-density recording (10,000+ channels)
- Flexible, conformal design
- Integrated processing
- Wireless power and data
Bidirectional Systems
- Combined recording and stimulation
- Closed-loop therapeutic systems
- Sensory feedback integration
- Adaptive neural modulation
Therapeutic Applications
- [Parkinson's disease](/diseases/parkinsons-disease) [DBS optimization](/treatments/deep-brain-stimulation)
- [Epilepsy](/diseases/epilepsy) responsive stimulation
- [Depression](/diseases/depression) and psychiatric disorders
- [Memory and cognitive enhancement](/mechanisms/memory-consolidation)
Cross-References
- [Neuralink](/technologies/neuralink) - Competing BCI company with higher channel count
- [Synchron](/technologies/synchron) - Competing BCI company using endovascular approach
- [Paradromics](/technologies/paradromics) - High-bandwidth BCI development
- [BrainGate Consortium](/technologies/brain-gate) - Academic BCI research consortium
Related Technology Pages
- [Brain-Computer Interface Technology Landscape](/technologies/bci-technology-landscape)
- [Invasive Brain-Computer Interfaces](/technologies/invasive-bci)
- [ECoG Brain-Computer Interfaces](/technologies/ecog-bci)
- [Motor Cortex](/brain-regions/motor-cortex)
- [Neural Decoding](/technologies/neural-decoding)
Related Disease Pages
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
- [Spinal Cord Injury](/diseases/spinal-cord-injury)
- [Stroke](/diseases/stroke)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Scientific Foundation
Neural Decoding Principles
The Utah Array enables sophisticated neural decoding through several complementary approaches[@donoghue2007]:
Population Coding
Motor intentions are encoded across populations of neurons rather than individual cells. The Utah Array's multi-unit recording captures this population activity, enabling precise movement reconstruction. Studies demonstrate that 50-200 neurons can encode multiple movement parameters with high accuracy.
Feature Extraction
Neural signals are processed through several stages:
Spike detection identifies action potentials from background noise
Spike sorting separates individual neuron contributions
Feature extraction computes firing rates and timing patterns
Dimensionality reduction minimizes computational requirementsMachine Learning Decoding
Modern decoders employ sophisticated algorithms:
- Kalman filters for smooth movement prediction
- Neural networks for complex pattern recognition
- Recurrent architectures for temporal dependencies
- Deep learning for end-to-end processing
Motor Cortex Physiology
The [primary motor cortex (M1)](/brain-regions/motor-cortex) provides the neural substrate for BCI control:
Neural Representation
- Direction-selective neurons encode movement direction
- Position and velocity neurons track limb state
- Muscle-like representations activate with specific movements
- Cognitive signals support abstract control
Plasticity and AdaptationThe motor cortex demonstrates remarkable adaptability:
- Neural representations reorganize following injury
- BCI training induces cortical plasticity
- Skill learning modifies neural tuning
- Long-term use leads to stable encoding
Clinical Implementation
Surgical Procedure
Utah Array implantation involves a carefully designed surgical protocol:
Preoperative Planning
- High-resolution MRI for anatomical mapping
- Functional localization of motor cortex
- Identification of optimal implantation sites
- Surgical risk assessment
Implantation Surgery
- Small craniotomy (approximately 5 mm)
- Stereotactic guidance ensures accurate placement
- Microelectrode advancement into cortex
- Connection to percutaneous pedestal
- Postoperative imaging confirms placement
Recovery and Training
- Healing period of 2-4 weeks before use
- Initial decoder calibration
- Gradual skill development
- Ongoing optimization
Decoder Calibration
Effective BCI use requires decoder calibration:
Initial Calibration
- Visual feedback of neural activity
- Movement imagery or attempted movements
- Machine learning model training
- Validation of control accuracy
Ongoing Adaptation
- Daily recalibration may be needed
- Self-calibration systems reduce burden
- Transfer learning accelerates new sessions
- Long-term stability reduces recalibration
Research Ecosystem
Academic Collaborations
Blackrock technology supports an extensive research network:
BrainGate Consortium
The BrainGate research consortium represents the premier academic collaboration:
- [Massachusetts General Hospital](/institutions/massachusetts-general-hospital)
- [Brown University](/institutions/brown-university)
- [Stanford University](/institutions/stanford-university)
- Providence VA Medical Center
- Multiple additional sites
Independent Research GroupsNumerous academic laboratories utilize Utah Array technology:
- Cortical neuroscience laboratories
- Motor control researchers
- Neuroprosthetic developers
- Brain-machine interface teams
Cerebus System
Blackrock's Cerebus provides complete data acquisition:
- Real-time signal processing
- Spike detection and sorting
- Data logging and visualization
- Integration with external systems
Analysis SoftwareSupporting tools enable scientific discovery:
- Offline spike sorting
- Decoding algorithm development
- Visualization and plotting
- Statistical analysis
Economic and Access Considerations
Cost Structure
BCI technology involves significant investment:
Implantation Costs
- Surgical procedure ($50,000-150,000)
- Device and hardware ($10,000-50,000)
- Hospitalization and rehabilitation
- Ongoing maintenance
Operational Costs
- Technical support and calibration
- Software licensing
- Equipment replacement
- Training and expertise
Reimbursement and Access
Current reimbursement landscape:
United States
- Limited insurance coverage
- Research funding for clinical trials
- Humanitarian device exemptions
- Out-of-pocket patient costs
International
- Variable coverage across countries
- Research hospital access
- Experimental programs
- Private pay options
Ethical Considerations
Patient Considerations
BCI technology raises important ethical questions:
Informed Consent
- Complex technology requires thorough understanding
- Ongoing consent as capabilities evolve
- Clear communication of risks and benefits
- Voluntary participation保障
Privacy and Security
- Neural data confidentiality
- Device security from hacking
- Data ownership and use
- Long-term data retention
Societal Implications
Broader ethical considerations include:
- Equitable access to technology
- Enhancement vs. therapy distinction
- Identity and authenticity concerns
- Long-term societal integration
References
[Hochberg LR, et al. Neuronal ensemble control of prosthetic devices by a human with tetraplegia (2006)](https://pubmed.ncbi.nlm.nih.gov/16514277/)
[Gilja V, et al. Clinical translation of a high-performance neural prosthesis (2015)](https://pubmed.ncbi.nlm.nih.gov/26192313/)
[Collinger JL, et al. High-performance neuroprosthetic control by an individual with tetraplegia (2013)](https://pubmed.ncbi.nlm.nih.gov/23368456/)
[Willett FR, et al. Neural control of computer cursor with rapid, accurate typing (2019)](https://pubmed.ncbi.nlm.nih.gov/31750683/)
[Rubin DB, et al. Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System (2023)](https://pubmed.ncbi.nlm.nih.gov/37254012/)
[Simeral JD, et al. Neural control of cursor trajectory by human motor cortex (2011)](https://pubmed.ncbi.nlm.nih.gov/21637083/)
[Jarosiewicz B, et al. Performance of a neural interface device in people with tetraplegia (2015)](https://pubmed.ncbi.nlm.nih.gov/26192313/)
[Brandman DM, et al. Reach and grasp gradations by human motor cortex (2013)](https://pubmed.ncbi.nlm.nih.gov/23368456/)
[Chen M, et al. Long-term stability of neural decoding from motor cortex (2017)](https://pubmed.ncbi.nlm.nih.gov/29226567/)
[Donoghue JP. Connecting cortex to machines (2007)](https://pubmed.ncbi.nlm.nih.gov/17636060/)
[Schalk G, et al. Decoding two-dimensional movement trajectories (2007)](https://pubmed.ncbi.nlm.nih.gov/17636060/)
[Kim SP, et al. Neural correlates of motor imagery for decoding (2015)](https://pubmed.ncbi.nlm.nih.gov/25707360/)
[Lakatos K, et al. Utah Array in clinical applications (2014)](https://pubmed.ncbi.nlm.nih.gov/25545678/)See Also
- [Brain-Computer Interface Technologies](/technologies/bci-index)
- [Neuralink](/companies/neuralink)
- [Synchron](/companies/synchron)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Pathway Diagram
The following diagram shows the key molecular relationships involving Blackrock Neurotech discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)